Acute lymphoblastic leukemia, version 2.2021

  • Patrick A. Brown
  • , Bijal Shah
  • , Anjali Advani
  • , Patricia Aoun
  • , Michael W. Boyer
  • , Patrick W. Burke
  • , Daniel J. DeAngelo
  • , Shira Dinner
  • , Amir T. Fathi
  • , Jordan Gauthier
  • , Nitin Jain
  • , Suzanne Kirby
  • , Michaela Liedtke
  • , Mark Litzow
  • , Aaron Logan
  • , Selina Luger
  • , Lori J. Maness
  • , Stephanie Massaro
  • , Ryan J. Mattison
  • , William May
  • Olalekan Oluwole, Jae Park, Amanda Przespolewski, Sravanti Rangaraju, Jeffrey E. Rubnitz, Geoffrey L. Uy, Madhuri Vusirikala, Matthew Wieduwilt, Beth Lynn, Ryan A. Berardi, Deborah A. Freedman-Cass, Mallory Campbell

Research output: Contribution to journalReview articlepeer-review

Abstract

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.

Original languageEnglish
Pages (from-to)1079-1109
Number of pages31
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
Issue number9
DOIs
StatePublished - Sep 2021

Fingerprint

Dive into the research topics of 'Acute lymphoblastic leukemia, version 2.2021'. Together they form a unique fingerprint.

Cite this